652 related articles for article (PubMed ID: 29545802)
61. Cytomegalovirus-Infected Primary Endothelial Cells Trigger NKG2C+ Natural Killer Cells.
Djaoud Z; Riou R; Gavlovsky PJ; Mehlal S; Bressollette C; Gérard N; Gagne K; Charreau B; Retière C
J Innate Immun; 2016; 8(4):374-85. PubMed ID: 27116381
[TBL] [Abstract][Full Text] [Related]
62. Cytomegalovirus-specific cytokine-induced killer cells: concurrent targeting of leukemia and cytomegalovirus.
Pfirrmann V; Oelsner S; Rettinger E; Huenecke S; Bonig H; Merker M; Wels WS; Cinatl J; Schubert R; Klingebiel T; Bader P
Cytotherapy; 2015 Aug; 17(8):1139-51. PubMed ID: 26072027
[TBL] [Abstract][Full Text] [Related]
63. Patterns of cytomegalovirus reactivation are associated with distinct evolutive profiles of immune reconstitution after allogeneic hematopoietic stem cell transplantation.
Moins-Teisserenc H; Busson M; Scieux C; Bajzik V; Cayuela JM; Clave E; de Latour RP; Agbalika F; Ribaud P; Robin M; Rocha V; Gluckman E; Charron D; Socié G; Toubert A
J Infect Dis; 2008 Sep; 198(6):818-26. PubMed ID: 18666855
[TBL] [Abstract][Full Text] [Related]
64. Favorable impact of natural killer cell reconstitution on chronic graft-versus-host disease and cytomegalovirus reactivation after allogeneic hematopoietic stem cell transplantation.
Kheav VD; Busson M; Scieux C; Peffault de Latour R; Maki G; Haas P; Mazeron MC; Carmagnat M; Masson E; Xhaard A; Robin M; Ribaud P; Dulphy N; Loiseau P; Charron D; Socié G; Toubert A; Moins-Teisserenc H
Haematologica; 2014 Dec; 99(12):1860-7. PubMed ID: 25085354
[TBL] [Abstract][Full Text] [Related]
65. Cytomegalovirus reactivation is associated with a lower rate of early relapse in myeloid malignancies independent of in-vivo T cell depletion strategy.
Hilal T; Slone S; Peterson S; Bodine C; Gul Z
Leuk Res; 2017 Jun; 57():37-44. PubMed ID: 28279876
[TBL] [Abstract][Full Text] [Related]
66. Diagnostic utility of human cytomegalovirus-specific T-cell response monitoring in predicting viremia in pediatric allogeneic stem-cell transplant patients.
Abate D; Cesaro S; Cofano S; Fiscon M; Saldan A; Varotto S; Mengoli C; Pillon M; Calore E; Biasolo MA; Cusinato R; Barzon L; Messina C; Carli M; Palù G
Transplantation; 2012 Mar; 93(5):536-42. PubMed ID: 22314338
[TBL] [Abstract][Full Text] [Related]
67. The immune response to cytomegalovirus in allogeneic hematopoietic stem cell transplant recipients.
Ciáurriz M; Zabalza A; Beloki L; Mansilla C; Pérez-Valderrama E; Lachén M; Bandrés E; Olavarría E; Ramírez N
Cell Mol Life Sci; 2015 Nov; 72(21):4049-62. PubMed ID: 26174234
[TBL] [Abstract][Full Text] [Related]
68. The transfer of adaptive immunity to CMV during hematopoietic stem cell transplantation is dependent on the specificity and phenotype of CMV-specific T cells in the donor.
Scheinberg P; Melenhorst JJ; Brenchley JM; Hill BJ; Hensel NF; Chattopadhyay PK; Roederer M; Picker LJ; Price DA; Barrett AJ; Douek DC
Blood; 2009 Dec; 114(24):5071-80. PubMed ID: 19776383
[TBL] [Abstract][Full Text] [Related]
69. Graft Engineering and Adoptive Immunotherapy: New Approaches to Promote Immune Tolerance After Hematopoietic Stem Cell Transplantation.
Bertaina A; Roncarolo MG
Front Immunol; 2019; 10():1342. PubMed ID: 31354695
[TBL] [Abstract][Full Text] [Related]
70. Modulation of the natural killer cell KIR repertoire by cytomegalovirus infection.
Charoudeh HN; Terszowski G; Czaja K; Gonzalez A; Schmitter K; Stern M
Eur J Immunol; 2013 Feb; 43(2):480-7. PubMed ID: 23161492
[TBL] [Abstract][Full Text] [Related]
71. Coordinated expansion of both memory T cells and NK cells in response to CMV infection in humans.
Bayard C; Lepetitcorps H; Roux A; Larsen M; Fastenackels S; Salle V; Vieillard V; Marchant A; Stern M; Boddaert J; Bajolle F; Appay V; Sauce D
Eur J Immunol; 2016 May; 46(5):1168-79. PubMed ID: 26910859
[TBL] [Abstract][Full Text] [Related]
72. Donor KIR genotype has a major influence on the rate of cytomegalovirus reactivation following T-cell replete stem cell transplantation.
Cook M; Briggs D; Craddock C; Mahendra P; Milligan D; Fegan C; Darbyshire P; Lawson S; Boxall E; Moss P
Blood; 2006 Feb; 107(3):1230-2. PubMed ID: 16239436
[TBL] [Abstract][Full Text] [Related]
73. Refining human T-cell immunotherapy of cytomegalovirus disease: a mouse model with 'humanized' antigen presentation as a new preclinical study tool.
Lemmermann NA; Reddehase MJ
Med Microbiol Immunol; 2016 Dec; 205(6):549-561. PubMed ID: 27539576
[TBL] [Abstract][Full Text] [Related]
74. Durable graft-versus-leukaemia effects without donor lymphocyte infusions - results of a phase II study of sequential T-replete allogeneic transplantation for high-risk acute myeloid leukaemia and myelodysplasia.
Davies JK; Hassan S; Sarker SJ; Besley C; Oakervee H; Smith M; Taussig D; Gribben JG; Cavenagh JD
Br J Haematol; 2018 Feb; 180(3):346-355. PubMed ID: 29076145
[TBL] [Abstract][Full Text] [Related]
75. CMV seronegative donors: Effect on clinical severity of CMV infection and reconstitution of CMV-specific immunity.
van der Heiden PLJ; van Egmond HM; Veld SAJ; van de Meent M; Eefting M; de Wreede LC; Halkes CJM; Falkenburg JHF; Marijt WAF; Jedema I
Transpl Immunol; 2018 Aug; 49():54-58. PubMed ID: 29679650
[TBL] [Abstract][Full Text] [Related]
76. Risk Factors for Cytomegalovirus Infection After Allogeneic Hematopoietic Cell Transplantation in Malignancies: Proposal for Classification.
Dziedzic M; Sadowska-Krawczenko I; Styczynski J
Anticancer Res; 2017 Dec; 37(12):6551-6556. PubMed ID: 29187429
[TBL] [Abstract][Full Text] [Related]
77. Impact of CMV and EBV on Immune Recovery After Allogeneic Hematopoietic Cell Transplantation in Children.
Pukownik E; Kubicka M; Kurylo-Rafinska B; Debski R; Galazka P; Czyzewski K; Krenska A; Bartoszewicz N; Demidowicz E; Marjańska A; Dziedzic M; Pogorzala M; Wysocki M; Styczynski J
Anticancer Res; 2018 Oct; 38(10):6009-6013. PubMed ID: 30275233
[TBL] [Abstract][Full Text] [Related]
78. Predictors for persistent cytomegalovirus reactivation after T-cell-depleted allogeneic hematopoietic stem cell transplantation.
Almyroudis NG; Jakubowski A; Jaffe D; Sepkowitz K; Pamer E; O'Reilly RJ; Papanicolaou GA
Transpl Infect Dis; 2007 Dec; 9(4):286-94. PubMed ID: 17511819
[TBL] [Abstract][Full Text] [Related]
79. Poor CMV-specific CD8+ T central memory subset recovery at early stage post-HSCT associates with refractory and recurrent CMV reactivation.
Liu J; Chang YJ; Yan CH; Xu LP; Jiang ZF; Zhang XH; Liu KY; Huang XJ
J Infect; 2016 Sep; 73(3):261-70. PubMed ID: 27311748
[TBL] [Abstract][Full Text] [Related]
80. Deciphering Effects of Uncontrolled Cytomegalovirus Replication on Immune Responses in Cytomegalovirus DNA-Positive Renal Transplant Recipients.
Makwana N; Waters S; Irish A; Howson P; Price P
Viral Immunol; 2019 Oct; 32(8):355-360. PubMed ID: 31536468
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
